Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review

por Arlegui, Hugo, Nachbaur, Gaëlle, Praet, Nicolas, Bégaud, Bernard
Publicado 2020

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

por Arlegui, Hugo, Bollaerts, Kaatje, Bauchau, Vincent, Nachbaur, Gaëlle, Bégaud, Bernard, Praet, Nicolas
Publicado 2020

Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis

por Ledent, Edouard, Arlegui, Hugo, Buyse, Hubert, Basile, Peter, Karkada, Naveen, Praet, Nicolas, Nachbaur, Gaëlle
Publicado 2018

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

por Arlegui, Hugo, Bollaerts, Kaatje, Salvo, Francesco, Bauchau, Vincent, Nachbaur, Gaëlle, Bégaud, Bernard, Praet, Nicolas
Publicado 2020

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

por BETTUZZI, Thomas, BACHELEZ, Hervé, BEYLOT-BARRY, Marie, ARLÉGUI, Hugo, PAUL, Carle, VIGUIER, Manuelle, MAHÉ, Emmanuel, BENETON, Nathalie, JULLIEN, Denis, RICHARD, Marie-Aleth, JOLY, Pascal, TUBACH, Florence, DUPUY, Alain, SBIDIAN, Emilie, CHOSIDOW, Olivier
Publicado 2022

Impact de l’épidémie de COVID-19 lors de la 1(ère) vague sur les patients de la cohorte PSOBIOTEQ traités pour psoriasis cutané

por Arlegui, Hugo, Mahé, Emmanuel, Richard, Marie-Aleth, Zago, Marilyn, De Rycke, Yann, Viguier, Manuelle, Beylot-Barry, Marie, Dupuy, Alain, Beneton, Nathalie, Joly, Pascal, Jullien, Denis, Bachelez, Hervé, Sbidian, Emilie, Chosidow, Olivier, Paul, Carle, Tubach, Florence
Publicado 2021